Combining anti-cancer CDK9 inhibitors with common antidepressants synergistically kills deadly brain tumors

Combining anti-cancer CDK9 inhibitors with common antidepressants synergistically kills deadly brain tumors

Diffuse midline glioma (DMG) is one of the most devastating childhood brain cancers, with almost no effective treatments. This study investigated how neurotransmitter signaling and epigenetic mechanisms might be targeted in combination to fight this cancer.

Researchers discovered that histone dopaminylation — a process where dopamine chemically modifies histone proteins to affect gene expression — plays a role in DMG's transcriptional activity. When CDK9 inhibitors (which block cancer-promoting gene transcription via RNA polymerase II) were combined with FDA-approved SSRIs (selective serotonin reuptake inhibitors, a class of common antidepressants), they synergistically reduced DMG cell growth. The combination altered histone dopaminylation patterns and repressed synaptic gene programs that tumors exploit.

This is clinically exciting because SSRIs are already FDA-approved, widely available, well-tolerated, and penetrate the brain. Combining them with CDK9 inhibitors — already in oncology trials — could provide a novel, accessible treatment approach for a cancer with no good options.

Key Findings

• Histone H3 dopaminylation contributes to oncogenic transcription in diffuse midline glioma
• CDK9 inhibitors combined with SSRIs synergistically reduce DMG cell growth
• The combination alters histone dopaminylation patterns and suppresses synaptic gene programs
• CaMKII modulates the response to CDK9 inhibition in DMG
• FDA-approved neuropsychiatric drugs show potential for repurposing in pediatric brain cancer

Implications

The discovery that FDA-approved SSRIs synergize with CDK9 inhibitors in DMG is immediately translatable — these drugs are safe, available, and blood-brain barrier penetrant. This could accelerate clinical testing for a cancer that desperately needs new options, and highlights that neurotransmitter-epigenetic crosstalk is a viable therapeutic target.

Caveats

Preprint, not peer reviewed. Findings are likely from cell lines and mouse models; human DMG clinical trials would be needed. SSRIs affect many pathways, and potential interactions or toxicities in pediatric patients with brain tumors need careful assessment. Summary based on abstract only.

Source: bioRxiv — 2026-04-10